FDA pharmacologic class
Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
6 medicines are in FDA's class of human immunodeficiency virus nucleoside analog reverse transcriptase inhibitors: lamivudine (Epivir), tenofovir disoproxil (Viread), abacavir (Ziagen), zidovudine (Retrovir), emtricitabine (Emtriva) and tenofovir alafenamide (Vemlidy); 17 combination products also contain one. 12 of the 23 are listed from generic labelers (FDA NDC Directory, October 8, 2026). The lowest pharmacy cost is tenofovir disoproxil fumarate 300 mg tablet at $0.294 per tablet (NADAC).
Which medicines are human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor?
| Medicine | Brand names | Generic labelers (all forms) | Pharmacy cost | Boxed warning | Shortage | Recalls since 2012 |
|---|---|---|---|---|---|---|
| Emtricitabine and tenofovir disoproxil | Truvada | 25 labelers | $0.529 per tablet 200-300 mg tablet | Yes | No current entry | 1 |
| Lamivudine | Epivir | 14 labelers | $0.489 per tablet 150 mg tablet | Yes | No current entry | 2 |
| Tenofovir disoproxil | Viread | 15 labelers | $0.294 per tablet 300 mg tablet | Yes | No current entry | 0 |
| Abacavir | Ziagen | 12 labelers | $0.546 per tablet 300 mg tablet | Yes | No current entry | 0 |
| Lamivudine and zidovudine | Combivir | 7 labelers | $0.771 per tablet Lamivudine-zidovudine tablet | Yes | No current entry | 1 |
| Zidovudine | Retrovir | 3 labelers | $0.464 per tablet 300 mg tablet | Yes | No current entry | 0 |
| Efavirenz and emtricitabine and tenofovir disoproxil | none listed | 7 labelers | $1.12 per tablet 600-200-300 mg tablet | Yes | No current entry | 0 |
| Abacavir and lamivudine | none listed | 6 labelers | $1.48 per unit 600-300 mg | Yes | No current entry | 0 |
| Emtricitabine | Emtriva | 2 labelers | $12.69 per capsule 200 mg capsule | Yes | A presentation being discontinued | 1 |
| Bictegravir and emtricitabine and tenofovir alafenamide | Biktarvy | none listed | $136.73 per tablet 50-200-25 mg tablet | Yes | No current entry | 0 |
| Efavirenz and lamivudine and tenofovir disoproxil | Symfi | 1 labeler | n/a | Yes | No current entry | 0 |
| Emtricitabine and rilpivirine and tenofovir disoproxil | Complera | 2 labelers | $114.50 per tablet 200-25-300 mg tablet | Yes | No current entry | 0 |
| Abacavir and dolutegravir and lamivudine | Triumeq | none listed | $130.01 per tablet 600-50-300 mg tablet | Yes | No current entry | 1 |
| Emtricitabine and tenofovir alafenamide | Descovy | none listed | $74.94 per tablet 200-25 mg tablet | Yes | No current entry | 0 |
| Abacavir and lamivudine and zidovudine | none listed | 1 labeler | n/a | Yes | No current entry | 0 |
| Cobicistat, darunavir, emtricitabine and tenofovir alafenamide | Symtuza | none listed | $152.87 per tablet 800-150-200-10 mg tablet | Yes | No current entry | 0 |
| Cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide | Genvoya | none listed | $143.35 per tablet Genvoya tablet | Yes | No current entry | 0 |
| Cobicistat, elvitegravir, emtricitabine and tenofovir disoproxil | Stribild | none listed | $150.14 per tablet Stribild tablet | Yes | No current entry | 0 |
| Dolutegravir and lamivudine | Dovato | none listed | $105.22 per tablet 50-300 mg tablet | Yes | No current entry | 0 |
| Doravirine and lamivudine and tenofovir disoproxil | Delstrigo | none listed | $93.06 per tablet 100-300-300 mg tablet | Yes | No current entry | 0 |
| Emtricitabine and rilpivirine and tenofovir alafenamide | Odefsey | none listed | $130.49 per tablet Odefsey tablet | Yes | No current entry | 0 |
| Lamivudine and tenofovir disoproxil | Cimduo | none listed | n/a | Yes | No current entry | 0 |
| Tenofovir alafenamide | Vemlidy | none listed | $51.98 per tablet 25 mg tablet | Yes | No current entry | 0 |
Source: FDA Established Pharmacologic Class (NDC Directory, openFDA); CMS NADAC of October 7, 2026; FDA shortages and recalls (FDA files October 8, 2026)
What do pharmacies pay?
Each medicine's most widely listed form, per unit, in the NADAC survey: what pharmacies paid, not what a patient pays; strengths differ, so compare like with like.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price